Sign Up to like & get
recommendations!
1
Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-112188
Abstract: Introduction Chronic myeloid leukemia (CML) is a stem cell disease characterized by the constitutive activity of the oncoprotein BCR-ABL that activates multiple signal transduction pathways. Tyrosine-kinase inhibitor (TKI) nilotinib successfully inhibits the activation and the…
read more here.
Keywords:
cd34 lin;
lin cells;
membership entity;
months nilotinib ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-6768
Abstract: The efficacy of nilotinib in patients with newly diagnosed Chronic Myeloid Leukemia (CML) has been extensively demonstrated in clinical trials (Sacha et al., Future Oncol. 2019). Although nilotinib provides superior overall survival and deeper molecular…
read more here.
Keywords:
treatment;
cd34 lin;
lin;
lin cells ... See more keywords